Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients

Abstract

The effect of lanthanum carbonate on abdominal aortic calcification (AAC) in the elderly maintenance hemodialysis (MHD) patients was investigated. Fifty-four cases subjected to routine MHD complicated with skin pruritus admitted to our hospital were selected and randomly divided into case group (n=28) and control group (n=26). The control group was given routine MHD alone. The case group was given lanthanum carbonate additionally on the basis of routine MHD. The changes of itching degrees at first and third month, and serum calcium, phosphorus, calcium-phosphorus products, intact parathyroid hormone (iPTH) levels and AAC scores at third month after treatments were compared between the two groups. The correlation between calcium-phosphorus products and AAC scores was also analyzed. There was no significant difference in the baseline of blood urea nitrogen (BUN), serum creatinine (Scr), uric acid, albumin, hemoglobin, C reactive protein (CRP), low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride, total cholesterol between case group and control group (P>0.05 for all). There was also no significant difference in the baseline itching scores between the case group and the control group (P>0.05). At 1st and 3rd month after treatment, the itching scores in the case group were 14.2±3.2 and 10.5±2.3, respectively, which were significantly lower than the baseline and those in the control group (P<0.05 for all). At 1st and 3rd month after treatment, the itching scores in the control group were 23.6±5.9 and 24.8±6.3, respectively, which were significantly higher than the baseline (P<0.05). There was no significant difference in the baseline of serum calcium, phosphorus, calcium-phosphorus products, iPTH levels between the case group and control group (P>0.05). At 3rd month after treatment, serum phosphorus, calcium-phosphorus products and iPTH levels in the case group were decreased significantly as compared with the baseline (P<0.05), and the serum calcium, phosphorus, calcium-phosphorus products, and iPTH levels were statistically decreased as compared with those in the control group (P<0.05). The AAC scores showed statistically significant difference between the case group and the control group (P<0.05). The serum phosphorus and AAC scores showed a positive correlation in both two groups. It was suggested that the administration of lanthanum carbonate in the elderly MHD patients can effectively relieve itching, and simultaneously reduce serum phosphorus and iPTH levels, resulting in the attenuation of vascular calcification.

Keywords

maintenance hemodialysis / lanthanum carbonate / intact parathyroid hormone / serum phosphorus / abdominal aortic calcification

References

[1] HolmarJ, UhlinF, FernströmA, et al. . An optical method for serum calcium and phosphorus level assessment during hemodialysis. Toxins, 2015, 7(3): 719-727 PMCID: 4379520 PMID: 25734785

[2] HutchisonAJ, MaesB, VanwalleghemJ, et al. . Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract, 2005, 100(1): 8-19

[3] KauppilaLI, PolakJF, CupplesLA, et al. . New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis, 1997, 132(2): 245-250 PMID: 9242971

[4] VerbekeF, Van BiesenW, HonkanenE, et al. . Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol, 2011, 6(1): 153-159 PMCID: 3022237 PMID: 20829424

[5] KuypersDR, ClaesK, EvenepoelP, et al. . A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant, 2004, 19(7): 1895-1901 PMID: 15150348

[6] PatelTS, FreedmanBI, YosipovitchG. An update on pruritus associated with CKD. Am J Kidney Dis, 2007, 50(1): 11-20 PMID: 17591521

[7] RamakrishnanK, BondTC, ClaxtonA, et al. . Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. Int J Nephrol Renovasc Dis, 2014, 7: 1-12 PMCID: 3872274

[8] MathurVS, LindbergJ, GermainM, et al. . A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol, 2010, 5(8): 1410-1419 PMCID: 2924419 PMID: 20558560

[9] MetzM, StänderS. Chronic pruritus—pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol, 2010, 24(11): 1249-1260 PMID: 20846147

[10] SpragueSM, MoeSM. The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol, 2013, 8(2): 313-318 PMCID: 3562858 PMID: 23037984

[11] ZangenehF, ClarkeBL, HurleyDL, et al. . Chronic kidney disease-mineral and bone disorders (CKD-MBDs): what the endocrinologist needs to know. Endocr Pract, 2014, 20(5): 500-516 PMID: 24325991

[12] AskarAM. Hyperphosphatemia. The hidden killer in chronic kidney disease. Saudi Med J, 2015, 36(1): 13-19 PMCID: 4362181 PMID: 25629999

[13] HoshinaM, WadaH, SakakuraK, et al. . Determinants of progression of aortic valve stenosis and outcome of adverse events in hemodialysis patients. J Cardiol, 2012, 59(1): 78-83 PMID: 22071482

[14] LishmanovA, DorairajanS, PakY, et al. . Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol, 2012, 44(2): 541-547 PMID: 21327525

[15] PowerA, ChanK, SinghSK, et al. . Appraising stroke risk in maintenance hemodialysis patients: a large single-center cohort study. Am J Kidney Dis, 2012, 59(2): 249-257 PMID: 21944665

[16] MohammedIA, HutchisonAJ. Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. Ther Clin Risk Manag, 2008, 4(5): 887-893 PMCID: 2621404 PMID: 19209270

[17] Ureña-TorresP, PriéD, KeddadK, et al. . Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrology, 2014, 15(1): 71-72 PMCID: 4107721 PMID: 24885942

[18] ZhaiCJ, YuXS, SunQL, et al. . Effect of lanthanum carbonate versus calcium based phosphate binders in dialysis patients: a meta-analysis. Clinical Nephrology, 2014, 82(12): 372-378 PMID: 25295578

[19] ReddyYN, SundaramV, AbrahamG, et al. . Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective. Int J Nephrol Renovasc Dis, 2014, 23(7): 391-399

[20] KettelerM, BiggarPH. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens, 2013, 22(4): 413-420 PMID: 23736841

[21] KestenbaumB, SampsonJN, RudserKD, et al. . Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol, 2005, 16(2): 520-528 PMID: 15615819

[22] CriquiMH, KamineniA, AllisonMA, et al. . Risk factor differences for aortic versus coronary calcified atherosclerosis: the multiethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol, 2010, 30(11): 2289-2296 PMCID: 2959146 PMID: 20814018